Published on October 23, 2012

Mary Greeley Medical Center Statement on FDA Advisory

Mary Greeley Medical Center is sending letters to patients who have received any injectable medication produced by the New England Compounding Center (NECC) after May 21, 2012. This is being done in the interest of acting with the utmost caution and concern for patient safety.

There is an ongoing investigation into several NECC products that may be connected to outbreaks of fungal infections in several states. Iowa is not among these states. Please note that Mary Greeley Medical Center does not use any of the NECC products connected to the investigation.  

However, over the course of the past several months, Mary Greeley Medical Center administered other NECC products. Acting on FDA recommendations, the medical center is notifying patients who received these other products to let them know of the situation and provide important information. Again, these other NECC products are not part of the investigation into the fungal infection outbreaks.

Patients will be informed that while the likelihood of an issue is low, it is important to be aware of symptoms to look out for and seek treatment from a health care provider if changes in health are noticed. Symptoms can include headache, worsening of a headache that was already present, fever, stiff neck, nausea and vomiting, or redness at the injection site.

Anyone with questions or concerns can contact the Mary Greeley Medical Center First Nurse at 1-800-524-6877 or 515-239-6877.  And for the latest information on this matter, please visit the FDA's website at www.fda.gov.